Intas Marbomet 150mg Advanced Veterinary Fluoroquinolone Antibacterial Tablets for Dogs & Cats – Marbofloxacin 150mg

Select Variant: 1 pack (10 tablets)

Description

Overcome multi-drug resistant bacterial challenges, resolve persistent deep pyoderma, and eliminate complicated urinary infections with Intas Marbomet 150mg Tablets, available online at VetMitra. In small animal clinical veterinary practice across India, bacterial infections frequently fail initial lines of therapy. Widespread prior use of standard beta-lactams and first-generation cephalosporins has led to resistant bacterial strains—most notably beta-lactamase-producing Staphylococcus pseudintermedius, Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae. When routine antibiotics stall, continuing with bacteriostatic or degraded drugs allows deep dermal scarring, irreversible renal parenchyma damage, or chronic pulmonary consolidation. Intas Marbomet 150mg provides advanced bactericidal efficacy powered by modern fluoroquinolone pharmacology: Dual-Enzyme Bactericidal DNA Cleavage (Marbofloxacin 150mg): An advanced carboxylic acid fluoroquinolone designed specifically for veterinary medicine. It penetrates bacterial cell envelopes and selectively binds to and inhibits two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. Halting these enzymes prevents DNA supercoiling, transcription, and cell division, triggering rapid autolytic fragmentation of the bacterial chromosome. Concentration-Dependent Pharmacodynamics (C max ​ /MIC): Unlike time-dependent beta-lactams that require constant blood levels, marbofloxacin exhibits concentration-dependent killing and a pronounced post-antibiotic effect (PAE). High peak plasma concentrations rapidly suppress bacterial reproduction, minimizing the emergence of resistant sub-populations. High Oral Bioavailability & Deep Tissue Distribution: Displays near-complete systemic oral absorption (~near 100%), with low plasma protein binding. It penetrates deeply into infected tissues, concentrating heavily in cutaneous tissue, bronchial secretions, pulmonary alveolar macrophages, prostatic fluid, and urine at levels exceeding serum concentrations. Effective Against Beta-Lactamase Producers: Because its molecular mode of action targets intracellular topoisomerases rather than cell-wall penicillin-binding proteins, marbofloxacin is unaffected by bacterial penicillinases, cephalosporinases, and extended-spectrum beta-lactamases (ESBLs). Feline Retinal Safety Profile: Unlike enrofloxacin—which carries a documented risk of irreversible, acute retinal degeneration and acute blindness in cats at standard to high doses—marbofloxacin demonstrates a significantly wider margin of ocular safety in feline medicine when dosed strictly at recommended levels. Convenient Once-Daily (SID) Dosing: High bioavailability and an extended elimination half-life support once-every-24-hours dosing, ensuring better owner compliance and reducing pet stress.